A long term study of men on testosterone therapy versus those that chose not to go on therapy found that the treated group reduced symptoms of benign prostate hypertrophy and erectile dysfunction.
We report significant decreases in the international prostate symptom score (IPSS) (p<0.0001) and post-voiding bladder volume (p<0.0001) in patients receiving TTh but not in the untreated group. We recorded a decrease in the Aging Males’ Symptoms scale (AMS) in the T-treated group but not in the untreated group (p<0.0001). We also recorded significant improvement in the international index of erectile function – erectile function domain (IIEF-EF) (p<0.0001) in the T-treated group, but not in untreated group, and was maintained throughout the follow-up period.